TY - JOUR
T1 - Workshop on idiopathic pulmonary fibrosis in older adults
AU - Castriotta, Richard J.
AU - Eldadah, Basil A.
AU - Foster, W. Michael
AU - Halter, Jeffrey B.
AU - Hazzard, William R.
AU - Kiley, James P.
AU - Talmadge, E. King
AU - Horne, Frances Mc Farland
AU - Nayfield, Susan G.
AU - Reynolds, Herbert Y.
AU - Schmader, Kenneth E.
AU - Toews, Galen B.
AU - High, Kevin P.
N1 - Funding Information:
Funding/Support: This workshop was supported by a grant from the John A. Hartford Foundation to the Association of Specialty Professors [Grant 2006-0239] .
Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Castriotta is a consultant for Blue Cross and Blue Shield of Texas and has received past research support from Cephalon, Inc. Dr Eldadah is a federal employee with the National Institutes of Health. Dr King serves as a consultant to the following pharmaceutical or medical device companies: Actelion, AstraZeneca, Boehringer Ingelheim, Centocor, Chronoger, CV Therapeutics, Domantis Limited, FibroGen, Genzyme, Human Genome Sciences, Huya Bioscience, InterMune, Millennium Pharmaceuticals, Merck, GlaxoSmithKline, Gilead, Novartis, Hoffman-La Roche, Inc., and Serono. He also serves on the advisory committees for Actelion and InterMune and on the data safety monitoring boards for Centocor and GlaxoSmithKline. Dr Nayfield is a federal employee with the National Institutes of Health. Dr Reynolds is a federal employee with the National Institutes of Health. Dr Schmader has received grant support from Merck and Wyeth and serves as a consultant for Merck and GlaxoSmithKline. Dr High has received grant support from Merck, Pfizer, Optimer, Chimerix, and Afexa Life Sciences, and serves as a consultant for Optimer and GlaxoSmithKline. Drs Foster, Halter, Hazzard, Kiley, McFarland Horne, and Toews have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2010/9/1
Y1 - 2010/9/1
N2 - Idiopathic pulmonary fibrosis (IPF), a heterogeneous disease with respect to clinical presentation and rates of progression, disproportionately affects older adults. The diagnosis of IPF is descriptive, based on clinical, radiologic, and histopathologic examination, and definitive diagnosis is hampered by poor interobserver agreement and lack of a consensus definition. There are no effective treatments. Cellular, molecular, genetic, and environmental risk factors have been identifi ed for IPF, but the initiating event and the characteristics of preclinical stages are not known. IPF is predominantly a disease of older adults, and the processes underlying normal aging might significantly influence the development of IPF. Yet, the biology of aging and the principles of medical care for this population have been typically ignored in basic, translational, or clinical IPF research. In August 2009, the Association of Specialty Professors, in collaboration with the American College of Chest Physicians, the American Geriatrics Society, the National Institute on Aging, and the National Heart, Lung, and Blood Institute, held a workshop, summarized herein, to review what is known, to identify research gaps at the interface of aging and IPF, and to suggest priority areas for future research. Efforts to answer the questions identified will require the integration of geriatrics, gerontology, and pulmonary research, but these efforts have great potential to improve care for patients with IPF.
AB - Idiopathic pulmonary fibrosis (IPF), a heterogeneous disease with respect to clinical presentation and rates of progression, disproportionately affects older adults. The diagnosis of IPF is descriptive, based on clinical, radiologic, and histopathologic examination, and definitive diagnosis is hampered by poor interobserver agreement and lack of a consensus definition. There are no effective treatments. Cellular, molecular, genetic, and environmental risk factors have been identifi ed for IPF, but the initiating event and the characteristics of preclinical stages are not known. IPF is predominantly a disease of older adults, and the processes underlying normal aging might significantly influence the development of IPF. Yet, the biology of aging and the principles of medical care for this population have been typically ignored in basic, translational, or clinical IPF research. In August 2009, the Association of Specialty Professors, in collaboration with the American College of Chest Physicians, the American Geriatrics Society, the National Institute on Aging, and the National Heart, Lung, and Blood Institute, held a workshop, summarized herein, to review what is known, to identify research gaps at the interface of aging and IPF, and to suggest priority areas for future research. Efforts to answer the questions identified will require the integration of geriatrics, gerontology, and pulmonary research, but these efforts have great potential to improve care for patients with IPF.
UR - http://www.scopus.com/inward/record.url?scp=77956793442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956793442&partnerID=8YFLogxK
U2 - 10.1378/chest.09-3006
DO - 10.1378/chest.09-3006
M3 - Review article
C2 - 20822991
AN - SCOPUS:77956793442
SN - 0012-3692
VL - 138
SP - 693
EP - 703
JO - CHEST
JF - CHEST
IS - 3
ER -